Solve Therapeutics has completed a $120 million unlabelled round as it advances a pair of antibody-drug conjugates (ADCs) for cancer that use its proprietary linker technology. San Diego-based Solve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback